Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating
Perspective Therapeutics Begins Shipping Investigational Products From State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey
Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $22
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21
Perspective Therapeutics, Inc (CATX): A Small-Cap Pioneer in Targeted Cancer Therapies
A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $21 to $22
Top Midday Decliners
Buy Rating Affirmed for Perspective Therapeutics Amid Promising Early-Stage Drug Results for Melanoma Treatment
Perspective Therapeutics Shares Fall After Melanoma Study Data Analysis
Gold Gains 1%; Wells Fargo Shares Gain After Q3 Earnings
12 Health Care Stocks Moving In Friday's Intraday Session
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
Dow Surges 150 Points; JPMorgan Posts Upbeat Earnings
Perspective Falls After Data for Radiopharmaceutical in Skin Cancer
Express News | Amex Halt Add Info Lst 9.660000
Perspective Therapeutics Says Initial Data Show Potential Melanoma Therapy's Safety, Efficacy
Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Raises Target Price to $22
Express News | Perspective Therapeutics to Advance Investigation of Potential First-in-Class Radiopharmaceutical Therapy [212PB]Vmt01 Based on Data Presented at the 21ST International Congress of the Society for Melanoma Research
Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day
Wedbush Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $25